Mugglehead
Subscribe
Egetis Therapeutics AB wins FDA approval for Emcitate in MCT8 deficiency

Egetis Therapeutics AB wins FDA approval for Emcitate in MCT8 deficiency

First U.S. approval covers peripheral thyrotoxicosis in MCT8 deficiency; Egetis expects commercial availability eight to 10 weeks after Sept. 28.

Mining & Critical Minerals

Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.

View all

Health & Science

Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.

View all

Markets & Technology

Technology, computing, crypto and cannabis, and the listed companies moving in them.

View all

Energy

Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.

View all

Cannabis & Psychedelics

Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.

View all